11
Nov
2020
Creating the Future of Microbiome-Based Therapies: Simba Gill on The Long Run
Today’s guest on The Long Run is Simba Gill. Simba is the CEO of Cambridge, Mass.-based Evelo Biosciences. Evelo is part of a new generation of biotech companies seeking to make medicines based on new understanding of the microbiome. The science here is fascinating. Evelo’s drug candidates are biologics designed to be taken orally, to act directly in the gut,... Read More
11
Nov
2020
So You Have a Cool Platform. The Next Decision Will Make or Break Your Company
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.